Insurance & Pensions

This bulletin series aims to provide an accessible yet rigorous overview of key topics in geroscience that may influence human health and lifespan. Our target audience includes anyone concerned with longevity risk including executives and modellers in the insurance industry, but also those working in public health and policy. We aim to equip these readers with a mental framework for understanding geroscience concepts that could impact longevity risks, helping them to follow relevant discussions in professional literature and to communicate effectively with colleagues about the emerging field of gerotherapeutics — interventions designed to slow the biological ageing process.

Our typical readers are highly educated non-specialists with limited time. To meet their needs, we provide a concise digest of evidence and simplified cognitive models of key concepts drawn from both academic and ‘grey’ literature — including reports, white papers, and other authoritative sources. This content is designed to be consumed in minutes rather than hours. We consciously avoid an overly academic style, instead focusing on accessible summaries, while intending to provide further detail in subsequent articles, reports, and white papers that elaborate on our methods and processes.

Key highlights:

• Two Essentials articles, covering important aspects of geroscience. These short-form articles will cover an important concept in geroscience, explore issues that arise from the impact of gero-therapeutics such as the impact on pensions, health care services and society in general.
• A Spotlight article where we investigate a potential gerotherapeutic intervention in detail, exploring which mechanisms of ageing it may affect and which ageing-related diseases could be eased. We will explore the potential impact using our own model of ageing, and discuss the implications for insurance products exposed to longevity risk.

Download first issue free
.

The short-form articles in the first issue outline the concept of the ‘Hallmarks of Ageing’ and our modelling approach, and the spotlight article explores the potential impact of mTOR inhibitors.

If you are interested in taking out a subscription to keep you and your team in touch with this important emerging area of longevity risk, email us at contact@crystallise.com.